Novan Therapeutics, a Durham company that is developing nitric oxide-based skin therapies, announced Wednesday positive Phase 2 clinical trial results for its acne therapy.
“The results from this Phase 2 study exceeded our expectations,” said Nate Stasko, Novan’s president, in a statement. “This data enables us to move forward with late stage clinical development for a fast acting, first-in-class new drug for acne.”
Novan began operations in January 2008 and has raised $20 million in private equity funding from individuals. The company has no drugs on the market.
In August, the company was awarded a $7.8 million government contract to develop a treatment for thermal burns. Novan's technology allows for the delivery of nitric oxide in controlled amounts for the treatment of different skin diseases and injuries.